Alirocumab in Patients with Sepsis

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 4, 2023

Primary Completion Date

February 18, 2025

Study Completion Date

February 23, 2025

Conditions
Sepsis
Interventions
DRUG

Alirocumab

A 600 mg dose of alirocumab (which is equivalent to 8mg/kg for a 75kg patient) will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.

DRUG

Placebo

A placebo to match a 600 mg dose of alirocumab will be administered once via IV over an approximately 30 ± 10 minute infusion using an infusion pump.

Trial Locations (2)

30303

Grady Memorial Hospital, Atlanta

30322

Emory University Hospital, Atlanta

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Jonathan Sevransky

OTHER